CollectionsJohnson Johnson
IN THE NEWS

Johnson Johnson

NEWS
January 23, 2012
The United States spends about $2.6 trillion per year on health care, or about 17.4 percent of our gross domestic product - more than most developed nations without correspondingly good results. The Justice Department has increased prosecution of health-care fraud, which can physically harm patients and fiscally injure taxpayers, against individuals or multinational companies. Philadelphia is a center for that fight because there are many health-care companies in the area.
BUSINESS
January 6, 2012 | By Margaret Cronin Fisk, Jef Feeley, and David Voreacos, Bloomberg News
Johnson & Johnson will pay more than $1 billion to the United States and most states to resolve a civil investigation into marketing of the antipsychotic Risperdal, according to people familiar with the matter. J&J, the world's largest health-products company, reached an accord last week with the U.S. attorney in Philadelphia, according to the sources, who were not authorized to speak about the matter. It doesn't resolve negotiations over a possible criminal plea, they said. The U.S. government has been investigating Risperdal sales practices since 2004, including allegations that the company marketed the drug for unapproved uses, J&J has said in Securities and Exchange Commission filings.
BUSINESS
January 5, 2012 | By David Sell, Inquirer Staff Writer
The little boy was 2 years old, and his name was River. On the night of July 22, 2010, he had a fever. Mothers and fathers worry about little boys with fevers, so Katy Moore gave her son Very Berry Strawberry Children's Tylenol. Within 30 minutes, he was spitting up blood. By the next day, he was dead from liver failure. In a lawsuit filed in Philadelphia Common Pleas Court, Daniel and Katy Moore of Ellensburg, Wash., southeast of Seattle, blame Tylenol's manufacturer, Johnson & Johnson Inc., and its McNeil Consumer Healthcare subsidiary, which has a plant and headquarters in Fort Washington, Montgomery County.
BUSINESS
December 23, 2011 | By David Sell, Inquirer Staff Writer
Patients and profits are often on opposite sides of the cost equation for pharmaceutical companies. That was evident this week, when Johnson & Johnson decided not to help an international nonprofit organization that tries to help provide AIDS drugs in poor nations at cheaper prices by making patent-protected drug formulas available to lower-cost manufacturers. J&J said three drugs, including one whose research was partially funded by U.S. taxpayers, would not be released to the Medicines Patent Pool.
NEWS
December 15, 2011
Synthes Inc. shareholders, meeting at the company's headquarters in Solothurn, Switzerland, voted to approve the proposal by Johnson & Johnson to take over Synthes for $21.3 billion in cash and stock. Synthes has facilities and a U.S. headquarters in Chester County. The companies hope to close the deal in the first half of 2012. "The shareholders approved the proposal to adopt the agreement and plan of merger as outlined in the invitation," Synthes said in a statement. The European Union is reviewing the deal to examine the antitrust effects on the market for screws, plates and other devices to fix bones broken through trauma or wear and tear.
BUSINESS
December 2, 2011 | By David Sell, Inquirer Staff Writer
Like many people, Michel Orsinger works for a company going through dramatic change because it has been acquired by a larger company. Unlike many people, Orsinger helped arrange the acquisition. Unlike almost anyone, Orsinger is getting $51.9 million for leaving the old company and a multimillion-dollar pay package from the new company. His new base salary of $700,000 will be a cut in pay from his old firm, but he will have some lucrative bonus opportunities. If he can make do clipping coupons for three years, he will get a stock package worth $17.2 million.
BUSINESS
November 28, 2011
Securities trades recently reported to the Securities and Exchange Commission by officers, directors, and principal shareholders of corporations based or having sizable employment in the Philadelphia area. Titles are as reported to the SEC. Amkor Technology Inc. Winston J. Churchill Jr. , director, sold 1,514 shares at $4.87 Nov. 16 and now indirectly holds 54,555 shares. Boeing Co. Thomas J. Downey , officer, sold 6,558 shares at $67.93 Nov. 15 and now directly holds 51,403 shares.
« Prev | 1 | 2 | 3 | 4 | 5 | Next »
|
|
|
|
|